Clinical trials: Knee OA
Osteoarthritis (OA) of the Knee, Knee Pain Arthritis
Neurolysis for the Treatment of Medial Chronic Knee Pain Due to Osteoarthritis
This study involves the use of sound waves to block pain signals caused by osteoarthritis of the knee. The sound waves are tightly focused on a specific area of the nerve.
- Conditions
- Osteoarthritis (OA) of the Knee, Knee Pain Arthritis, Chronic Knee Pain
- Trial name
- NCT07178951
- Testing
- Neurotomy of the medial sensory articular branches
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- FUSMobile Inc.
Osteoarthritis, Pain
Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain
The objectives of this trial are to investigate the efficacy and safety of six weeks of treatment with OLT1177 Gel in subjects with moderate to severe pain associated with osteoarthritis of the knee following cessation of pain…
- Trial name
- NCT02104050
- Testing
- OLT1177 Gel
- Where
- 13 sites in United States
- Volunteers
- 202 people
- Sponsor
- Olatec Therapeutics, Inc.
Osteoarthritis of the Knee
Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee
The objectives of this study were to characterize the local extent and duration of exposure of TA from FX006 and TCA IR, characterize the systemic PK of FX006 and TCA IR, and assess the safety and general tolerability of a single…
- Trial name
- NCT02637323
- Testing
- FX006 32 mg, TCA IR 40
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Osteoarthritis, Pain
Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of fulranumab as Monotherapy compared with placebo in participants with signs and symptoms of osteoarthritis of the hip or knee that are not…
- Trial name
- NCT02336698
- Testing
- Fulranumab 1 mg, Fulranumab 3 mg
- Where
- 32 sites in United States, Poland and 2 more
- Volunteers
- 18 people
- Sponsor
- Janssen Research & Development, LLC
Knee Osteoarthritis
Hymovis™ Versus Placebo in Knee Osteoarthritis
Purpose: The purpose of this study is to demonstrate if the intra-articular injection of a new viscoelastic Hydrogel (Hymovis) is superior to Placebo (phosphate buffered saline [PBS] in subjects with symptomatic osteoarthritis of…
- Trial name
- Hymovis (NCT01372475)
- Testing
- Hymovis Intra-articular Injection, Phosphate Buffered Saline Injection
- Where
- 33 sites in United States, Puerto Rico
- Volunteers
- 800 people
- Sponsor
- Fidia Farmaceutici s.p.a.
Knee Osteoarthritis
GAE Using Embosphere Microspheres vs Corticosteroid Injections for Treatment of Symptomatic Knee OA (MOTION)
This multicenter, prospective, interventional trial is designed to assess the outcome of subjects with symptomatic knee osteoarthritis (OA) that are randomized to treatment with either genicular artery embolization (GAE) using…
- Trial name
- MOTION (NCT05818150)
- Testing
- Embosphere Microspheres, Corticosteroid injection
- Where
- 27 sites in United States, Australia and 4 more
- Volunteers
- 264 people
- Sponsor
- Merit Medical Systems, Inc.
Osteoarthritis, Knee
Efficacy and Safety of Lumiracoxib in Patients With Knee Osteoarthritis (OA).
This study will investigate the efficacy and safety of lumiracoxib in patients with primary knee osteoarthritis (OA).
- Trial name
- NCT00366938
- Testing
- Lumiracoxib
- Where
- United States
- Volunteers
- 1,464 people
- Sponsor
- Novartis
Knee Osteoarthritis
Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)
This study will evaluate the efficacy and safety of using lumiracoxib in the treatment of patients with knee osteoarthritis (OA)
- Trial name
- NCT00367315
- Testing
- Lumiracoxib
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 1,684 people
- Sponsor
- Novartis
Osteoarthritis, Knee
The Safety/Efficacy of hUC Mesenchymal Stem Cells（19#iSCLife®-OA） Therapy for Patients With Osteoarthritis
The purpose of this study is verify the efficacy and safety of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) therapy for patients with Osteoarthritis, and in addition, provide basis for exploring the treatment regimen of…
- Trial name
- NCT03383081
- Testing
- Low dose mesenchymal stem cells, High dose mesenchymal stem cells, Intraarticular injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sclnow Biotechnology Co., Ltd.
Osteoarthritis of the Knee
A 4-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Knee Osteoarthritis
A 4-week, Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects with Osteoarthritis (OA) of the Knee
- Trial name
- HP-5000 (NCT03277066)
- Testing
- Diclofenac Sodium Active Topical Patch 1, Diclofenac Sodium Active Topical Patch 2
- Where
- United States
- Volunteers
- 289 people
- Sponsor
- Noven Pharmaceuticals, Inc.
Knee Osteoarthritis, Intra-Articular Injection
Innovative Tool to Analyse Synovial Fluid of Patients With Knee Ostearthritis After IA Injection of Synvisc-one®
The objective of this trial is to assess the clinical pertinence of an innovative analytical tool (SYNODIAG) to analyze the Synovial Fluid (SF) composition and guide the patient treatment in a Proof of Concept (PoC) study using…
- Trial name
- RESYF (NCT04321668)
- Testing
- Synvisc-One
- Where
- 3 sites in Belgium
- Volunteers
- 13 people
- Sponsor
- Pulsalys
Osteoarthritis
Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase
The purpose of the extension phase is to evaluate the long-term safety and tolerability of buprenorphine transdermal system (BTDS).
- Trial name
- NCT01141283
- Testing
- Buprenorphine transdermal patch
- Where
- 42 sites in United States
- Volunteers
- 290 people
- Sponsor
- Purdue Pharma LP
Chronic Pain
A Double-blind Study of Controlled Release OROS Hydromorphone Compared to Placebo in Patients With Chronic Osteoarthritis (OA) Pain
To evaluate the efficacy of OROS Hydromorphone in reducing moderate to severe chronic pain in patients with Osteoarthritis (OA) Pain
- Trial name
- NCT00631319
- Testing
- OROS hydromorphone
- Volunteers
- 343 people
- Sponsor
- Mallinckrodt